ThioBridge™: Linking Antibody to Drug with ThioBridge™ Conjugation Technology for Better ADCs

Improve your antibody-drug conjugate design and delivery with our ThioBridge™ conjugation technology platform

In the development of antibody-drug conjugates (ADCs), linker technologies are a critical component, particularly those used in first-generation ADC bioconjugation. In our experience, these often have limitations that can impact the safety and efficacy of the ADC.

Why choose ThioBridge™?

We developed ThioBridge™ to overcome the limitations associated with traditional linker technologies. Improving the design and delivery of ADCs.

Abzena’s bioconjugation and antibody-drug conjugate expertise

We are a leading, fully integrated bioconjugates & ADCs contract development and manufacturing organization (CDMO). For over 20 years we have refined our expertise in bioconjugation and conjugates to create end-to-end solutions including our ThioBridge™ ADC development platform.

Discover our antibody-drug conjugate services.

Download our info sheet now to learn more about the potential benefits of this newly enhanced platform.

Download Info Sheet